An Australian court has pulled Nurofen's pain relief products from shelves, ruling that it misled consumers over its performance.
The UK-based pharmaceutical company has several products that it claims specific symptons, such as migraines or back pain. But the court found that the products are identical.
These specific products were also found to have been sold at almost double the price of Nurofen's standard pain relief.
Reckitt Benckiser, which produces Nurofen, said it "did not set out to mislead consumers", but stressed that the ruling only applies to products in Australia.
Australia's consumer watchdog, which brought the case to court earlier this year, said the range of products "was formulated to treat a particular type of pain; and solely or specifically treated a particular type of pain". It said the range was "no more effective at treating the type of pain described on its packaging than any of the other Nurofen specific pain products."